Neos Therapeutics, Inc. (NASDAQ: NEOS) completed the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE